Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.

Autor:	Ainsua-Enrich E; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Pedreño-Lopez N; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Bracke C; Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Ávila-Nieto C; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Rodríguez de la Concepción ML; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Pradenas E; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Trinité B; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Marfil S; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Miranda C; Fight AIDS Foundation, Badalona, Catalonia 08916, Spain., González S; Fight AIDS Foundation, Badalona, Catalonia 08916, Spain., Toledo R; Fight AIDS Foundation, Badalona, Catalonia 08916, Spain., Font M; Fight AIDS Foundation, Badalona, Catalonia 08916, Spain., Benet S; Fight AIDS Foundation, Badalona, Catalonia 08916, Spain., Escribà T; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Jimenez-Moyano E; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Peña R; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Cedeño S; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Prado JG; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.; Germans Trias i Pujol Research Institute (IGTP), Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Mothe B; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain., Brander C; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Catalonia 08010, Spain.; University of Vic, Central University of Catalonia, Vic, Catalonia 08500, Spain., Izquierdo-Useros N; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.; Germans Trias i Pujol Research Institute (IGTP), Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Vergara-Alert J; Unitat mixta d'Investigació IRTA-UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Universitat Autonoma de Barcelona, Bellaterra, Catalonia 08193, Spain.; IRTA. Programa de Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Universitat Autònoma de Barcelona, Bellaterra, Catalonia 08193, Spain., Segalés J; Unitat mixta d'Investigació IRTA-UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Universitat Autonoma de Barcelona, Bellaterra, Catalonia 08193, Spain.; Departament de Sanitat i Anatomia animal, Facultat de Veterinaria, Universitat Autonoma de Barcelona, Bellaterra, Catalonia 08193, Spain., Massanella M; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain., Benitez RM; Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Romero A; Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Molina-Morant D; Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain., Blanco J; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.; Germans Trias i Pujol Research Institute (IGTP), Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; University of Vic, Central University of Catalonia, Vic, Catalonia 08500, Spain., Clotet B; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.; Respiratory Diseases Networking Biomedical Research Center (CIBERes), Carlos III Health Institute, Madrid, Spain., Mateu L; Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Departament de Sanitat i Anatomia animal, Facultat de Veterinaria, Universitat Autonoma de Barcelona, Bellaterra, Catalonia 08193, Spain., Pedro-Botet ML; Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Respiratory Diseases Networking Biomedical Research Center (CIBERes), Carlos III Health Institute, Madrid, Spain.; Universitat Autónoma de Barcelona, Bellaterra, Catalonia 08193, Spain., Carrillo J; IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.; Infectious Disease Networking Biomedical Research Center (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.; Germans Trias i Pujol Research Institute (IGTP), Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.
Jazyk:	angličtina
Zdroj:	IScience [iScience] 2022 Nov 18; Vol. 25 (11), pp. 105455. Date of Electronic Publication: 2022 Oct 28.
DOI:	10.1016/j.isci.2022.105455
Abstrakt:	Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n = 9), common variable immunodeficiency (CVID, n = 12), combined immunodeficiency (CID, n = 1), and thymoma with immunodeficiency (TID, n = 1). unPAD patients and healthy controls (HCs, n = 10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Of interest, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8 + T cells. CID and TID patients developed cellular but not humoral responses. Although the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies. Competing Interests: The authors declare no competing interests. Unrelated to the submitted work, JB and JC are founders and shareholders of AlbaJuna Therapeutics, S.L. BC is founder and shareholder of AlbaJuna Therapeutics, S.L. and AELIX Therapeutics, S.L. (© 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu